Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer

3 episodes

0.50 program credits

28m

Details

Episodes

Presenters

Overview
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Provider(s)/Educational Partner(s)
Jointly provided by
Support for this activity has been provided through an educational grant from Astellas and Pfizer, Inc.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, urologists, advanced practice providers, nurses, and other health care providers (HCPs) involved in the care of patients with bladder cancer.
Learning Objectives
After completing this activity, participants should be better able to:
- Summarize guideline-based evidence supporting individualized treatment strategies that incorporate antibody-drug conjugates (ADCs) in the first-line setting for locally advanced or metastatic bladder cancer in accordance with clinical guidelines
- Describe multidisciplinary monitoring and management strategies for AEs associated with ADC use in patients with locally advanced or metastatic bladder cancer
- Interpret emerging clinical trial data on the effectiveness of perioperative immunotherapies for the management of patients with MIBC
Accreditation and Credit Designation Statements
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the Bladder Cancer Advocacy Network (BCAN), and RedMedEd. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you must pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PACE’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6–8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving PACE permission to use this information/data to report your participation to these boards’ JA-PARS.
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Elizabeth R. Plimack, MD, MS, FASCO, has disclosed the following relevant financial relationships:
Consultant, Advisor, Speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, EMD Serono, Merck, Pfizer, SeaGen, Signatera, Synthekine, Aura Biosciences, Adaptimmune, 23andMe
Lillibeth Velasco, MSN, RN, has disclosed no relevant financial relationships.
Partners for Advancing Clinical Education (PACE)
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Bladder Cancer Advocacy Network (BCAN)
The BCAN planners have disclosed no relevant financial relationships.
RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest and evaluation. Certificates can be printed immediately.
Contact Information
For questions regarding CME credit or additional information about the accreditation of this activity, please visit partnersed.com.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.
Privacy
This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit forthis activity is provided by PACE. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the PACE so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through PACE or RedMedEd. For more information, contact or education@redmeded.com.
Copyright
© 2025. This CME/CE-certified program is held as copyrighted by BCAN and RedMedEd. Through this notice, BCAN and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 02/21/2025
Expiration Date: 02/21/2026